Hearing Test Response May ID Newborns at Risk for Autism
THURSDAY, Nov. 19, 2020 -- Newborns exhibit neurophysiological variation associated with autism spectrum disorder (ASD), according to a report published online Nov. 2 in Autism Research.
Oren Miron, from Harvard Medical School in Boston, and colleagues collected auditory brainstem response (ABR) data on 139,154 newborns from their Universal Newborn Hearing Screening, including 321 who were subsequently diagnosed with ASD.
The researchers found that compared with the non-ASD newborns, ASD newborns had significant prolongations of the ABR phase and V-negative latency. Compared with previous studies in older ASD samples, newborns in the ASD group also exhibited greater variance in their latencies; this was likely partially due to low intensity of the ABR stimulus.
"We know autism spectrum disorder is connected to how children process sound, so even if the child's hearing is normal, it can still be processed differently," a coauthor said in a statement. "With better understanding of how ABR testing can be used to identify at-risk babies, we can flag children who might be at risk."
© 2020 HealthDay. All rights reserved.
Posted: November 2020
Read this next
THURSDAY, Oct. 29, 2020 -- Maternal use of valproic acid, but not lamotrigine, is associated with an increased risk for autism spectrum disorder (ASD) and...
MONDAY, Oct. 19, 2020 -- Children with autism spectrum disorder (ASD) and/or attention-deficit/hyperactivity disorder (ADHD) have more doctor and hospital visits during infancy,...
WEDNESDAY, Oct. 14, 2020 -- Exposure to maternal epidural analgesia during vaginal delivery may increase the later risk for autism spectrum disorders (ASD) for children, according...
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
- Monthly Update Archive
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.